Anaptysbio, INC: management transactions · United States · SEC (Form 4)

About Anaptysbio, INC

AnaptysBio, Inc. is a U.S.-based biotechnology company headquartered in San Diego, California, and listed on the Nasdaq Global Select Market under the ticker ANAB. For investors in French-, Belgian-, and Swiss-markets, the company is best understood as an immunology-focused biotech with a hybrid economic profile: it combines development-stage pipeline assets with royalty and collaboration economics tied to partnered programs. That mix makes AnaptysBio materially different from a classic single-asset or purely pre-revenue biotech. The company was founded in the 2000s and built its reputation on antibody discovery and immune-pathway targeting. Over time, AnaptysBio evolved from a research-heavy organization into a more strategically segmented business model, using partnerships to monetize certain assets while continuing to advance internally controlled programs. Its shares have traded on Nasdaq since 2017, which has helped position the company within the U.S. public-market biotechnology ecosystem and given it access to a broad investor base that tends to reward scientific optionality and partnership value. Today, the company’s most visible commercial and financial drivers are its collaborations around Jemperli with GSK and imsidolimab with Vanda, alongside an internal biopharma portfolio. On the development side, the pipeline includes rosnilimab, ANB033, and ANB101. The company has highlighted immunology indications such as ulcerative colitis, rheumatoid arthritis, celiac disease, eosinophilic esophagitis, and generalized pustular psoriasis. This is a focused but high-risk therapeutic area: the addressable market opportunity can be large, but clinical execution and differentiation are essential because immunology is crowded and highly competitive. From a market-position standpoint, AnaptysBio competes with both large multinational pharma groups and specialized biotechnology companies pursuing inflammatory and autoimmune diseases. Its differentiation lies in a combination of scientific expertise, partnered assets that may generate royalties or milestone income, and a pipeline that could create upside if clinical data are positive. The company’s strategic objective appears to be value realization through both development success and portfolio simplification. Recent news has been especially important. In 2026, AnaptysBio reported first-quarter results, continued to discuss a planned separation of its biopharma operations from its royalty assets, announced leadership and board changes, and authorized a $100 million share repurchase program. It also updated the market on clinical progress and setbacks: rosnilimab produced meaningful development data in rheumatoid arthritis, while its phase 2 ulcerative colitis study missed primary and secondary endpoints. These developments underscore a key point for equity investors: AnaptysBio is an event-driven Nasdaq biotech in the United States, where valuation is likely to be shaped by clinical readouts, partnership economics, and the execution of its planned corporate separation.